214 related articles for article (PubMed ID: 22152173)
21. Cost-effectiveness of first-line antiretroviral therapy for HIV-infected African children less than 3 years of age.
Ciaranello AL; Doherty K; Penazzato M; Lindsey JC; Harrison L; Kelly K; Walensky RP; Essajee S; Losina E; Muhe L; Wools-Kaloustian K; Ayaya S; Weinstein MC; Palumbo P; Freedberg KA
AIDS; 2015 Jun; 29(10):1247-59. PubMed ID: 25870982
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness of combination therapy with etravirine in treatment-experienced adults with HIV-1 infection.
Mauskopf J; Brogan AJ; Talbird SE; Martin S
AIDS; 2012 Jan; 26(3):355-64. PubMed ID: 22089378
[TBL] [Abstract][Full Text] [Related]
23. Cost effectiveness of darunavir/ritonavir combination antiretroviral therapy for treatment-naive adults with HIV-1 infection in Canada.
Brogan AJ; Smets E; Mauskopf JA; Manuel SA; Adriaenssen I
Pharmacoeconomics; 2014 Sep; 32(9):903-17. PubMed ID: 24906477
[TBL] [Abstract][Full Text] [Related]
24. Optimizing treatment for HIV-infected South African women exposed to single-dose nevirapine: balancing efficacy and cost.
Holmes CB; Zheng H; Martinson NA; Freedberg KA; Walensky RP
Clin Infect Dis; 2006 Jun; 42(12):1772-80. PubMed ID: 16705586
[TBL] [Abstract][Full Text] [Related]
25. [Lopinavir/ritonavir in HIV-infected patient with long-term virological failure: immunovirological response and tolerance in 121 patients of the ANRS CO8 Aproco-Copilote cohort].
Brunet-François C; Taieb A; Masquelier B; Le Moing V; Lewden C; Dellamonica P; Cuzin L; Allavena C; Spire B; Chêne G; Raffi F;
Med Mal Infect; 2007 Mar; 37(3):172-7. PubMed ID: 17239554
[TBL] [Abstract][Full Text] [Related]
26. When to initiate highly active antiretroviral therapy in sub-Saharan Africa? A South African cost-effectiveness study.
Badri M; Cleary S; Maartens G; Pitt J; Bekker LG; Orrell C; Wood R
Antivir Ther; 2006; 11(1):63-72. PubMed ID: 16518961
[TBL] [Abstract][Full Text] [Related]
27. The cost-effectiveness of treatment with lamivudine and zidovudine compared with zidovudine alone: a comparison of Markov model and trial data estimates.
Mauskopf J; Lacey L; Kempel A; Simpson K
Am J Manag Care; 1998 Jul; 4(7):1004-12. PubMed ID: 10181990
[TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy.
Sanders GD; Bayoumi AM; Sundaram V; Bilir SP; Neukermans CP; Rydzak CE; Douglass LR; Lazzeroni LC; Holodniy M; Owens DK
N Engl J Med; 2005 Feb; 352(6):570-85. PubMed ID: 15703422
[TBL] [Abstract][Full Text] [Related]
29. Predictive factors of lopinavir/ritonavir discontinuation for drug-related toxicity: results from a cohort of 416 multi-experienced HIV-infected individuals.
Bongiovanni M; Cicconi P; Landonio S; Meraviglia P; Testa L; Di Biagio A; Chiesa E; Tordato F; Bini T; Monforte Ad
Int J Antimicrob Agents; 2005 Jul; 26(1):88-91. PubMed ID: 15878262
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness of genotypic antiretroviral resistance testing in HIV-infected patients with treatment failure.
Sendi P; Günthard HF; Simcock M; Ledergerber B; Schüpbach J; Battegay M;
PLoS One; 2007 Jan; 2(1):e173. PubMed ID: 17245449
[TBL] [Abstract][Full Text] [Related]
31. A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations.
Pinheiro Edos S; Antunes OA; Fortunak JM
Antiviral Res; 2008 Sep; 79(3):143-65. PubMed ID: 18571246
[TBL] [Abstract][Full Text] [Related]
32. Treatment outcomes amongst previously antiretroviral-naïve HIV-infected patients starting lopinavir/ritonavir-containing antiretroviral regimens at the Royal Free Hospital.
Smith CJ; Phillips AN; Youle MS; Sabin CA; Lampe FC; Tsintas R; Tyrer M; Johnson MA
HIV Med; 2007 Jan; 8(1):55-63. PubMed ID: 17305933
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness of transcranial magnetic stimulation in the treatment of major depression: a health economics analysis.
Simpson KN; Welch MJ; Kozel FA; Demitrack MA; Nahas Z
Adv Ther; 2009 Mar; 26(3):346-68. PubMed ID: 19330495
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness of chemoprophylaxis after occupational exposure to HIV.
Pinkerton SD; Holtgrave DR; Pinkerton HJ
Arch Intern Med; 1997 Sep; 157(17):1972-80. PubMed ID: 9308509
[TBL] [Abstract][Full Text] [Related]
35. Cost/efficacy analysis of preferred Spanish AIDS study group regimens and the dual therapy with lopinavir/ritonavir plus lamivudine for initial ART in HIV infected adults.
Gatell Artigas JM; Arribas López JR; Lázaro Y de Mercado P; Blasco Bravo AJ
Enferm Infecc Microbiol Clin; 2016; 34(7):427-30. PubMed ID: 25749416
[TBL] [Abstract][Full Text] [Related]
36. Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance.
Molina JM; Ait-Khaled M; Rinaldi R; Penco G; Baril JG; Cauda R; Soriano V; Pialoux G; Wire MB; Lou Y; Givens N; Craig C; Nichols WG; Barbosa I; Yeo J;
J Antimicrob Chemother; 2009 Aug; 64(2):398-410. PubMed ID: 19515730
[TBL] [Abstract][Full Text] [Related]
37. Lopinavir/ritonavir-based antiretroviral therapy in human immunodeficiency virus type 1-infected naive children: rare protease inhibitor resistance mutations but high lamivudine/emtricitabine resistance at the time of virologic failure.
Frange P; Briand N; Avettand-fenoel V; Veber F; Moshous D; Mahlaoui N; Rouzioux C; Blanche S; Chaix ML
Pediatr Infect Dis J; 2011 Aug; 30(8):684-8. PubMed ID: 21427626
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness of laboratory monitoring for management of HIV treatment in sub-Saharan Africa: a model-based analysis.
Hamers RL; Sawyer AW; Tuohy M; Stevens WS; Rinke de Wit TF; Hill AM;
AIDS; 2012 Aug; 26(13):1663-72. PubMed ID: 22695297
[TBL] [Abstract][Full Text] [Related]
39. Cost effectiveness of darunavir/ritonavir in highly treatment-experienced, HIV-1-infected adults in the USA.
Mauskopf J; Brogan A; Martin S; Smets E
Pharmacoeconomics; 2010; 28 Suppl 1():83-105. PubMed ID: 21182346
[TBL] [Abstract][Full Text] [Related]
40. Cost effectiveness of darunavir/ritonavir 600/100 mg bid in protease inhibitor-experienced, HIV-1-infected adults in Belgium, Italy, Sweden and the UK.
Moeremans K; Annemans L; Löthgren M; Allegri G; Wyffels V; Hemmet L; Caekelbergh K; Smets E
Pharmacoeconomics; 2010; 28 Suppl 1():107-28. PubMed ID: 21182347
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]